drugset / Trial / NCT04518319
Clinical Intervention on Cognitive Impairment of Schizophrenia With Metabolic Syndrome
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a single-center, randomized, parallel-control study conducted in schizophrenic inpatients with metabolic syndrome who have been conducted with olanzapine. The purpose of this study is to evaluate the efficacy and safety of omega-3 polyunsaturated fatty acids, Xbox aerobic exercise and transcranial direct current stimulation( tDCS). Following a screening period, subjects who meet the entry criteria will be randomized to treated with omega-3 polyunsaturated fatty acids1.2mg per day, Xbox aerobic exercise 30min per day and tDCS at 2mA, 20 min(5 session/week) for 12 weeks.
Timeline
- Start
- 2020-10-01
- Primary completion
- 2024-11
- Completion
- 2024-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olanzapine | Small molecule | — | — |
| Subject | Omega-3 fatty acids | Unknown | 1200 mg | — |